atepeq/tico19 huggingface dataset:
The FDA in the United States approved the first point-of-care test on 21 March 2020 for use at the end of that month.Diagnostic guidelines released by Zhongnan Hospital of Wuhan University suggested methods for detecting infections based upon clinical features and epidemiological risk.
FDA ta cikin jihar America ta amince da batun kulawa ta farko a ranar 21 ga wata Maris shekara ta 2020 don anfani a qarshen waccan watan. Jagorar ganewar asali ta fito daga asibitin Zhongnan na Jami'ar wuhan ta bada shawarwaru ga hanyoyin gano cuta dangane da sifofin asibiti da hadarin kwayar cutar.
Bilateral multilobar ground-glass opacities with a peripheral, asymmetric and posterior distribution are common in early infection.
Hadin multilubar, gilashin kasa opacitiea tare da yanki asymmetry dakuma rarraba gaba suna da yawa a farkon kamuwa da cuta.
Subpleural dominance, crazy paving (lobular septal thickening with variable alveolar filling), and consolidation may appear as the disease progresses.
Mamayewar subpleural, fasa hauka, da karfafawa na iya fitowa yayinda cutan na girma.
Few data are available about microscopic lesions and the pathophysiology of COVID-19.
Babu bayani sosai a kan cutar COVID-19.
The main pathological findings at autopsy are:
Babban ganowa da aka yi daga binciken gawaki sune:
Macroscopy: pleurisy, pericarditis, lung consolidation and pulmonary oedema
Macroscopy: plerisy, pericarditis, inganci huhu da pulmonary oedema.
Four types of severity of viral pneumonia can be observed:
Za a iya lura da tsananin zafin cutar huhu guda hudu:
mild pneumonia: pulmonary oedema, pneumocyte hyperplasia, large atypical pneumocytes, interstitial inflammation with lymphocytic infiltration and multinucleated giant cell formation
nimoniya wanda bai tsananta ba: pulmonary oedema, pneumocyte hyperplasia, babbar atypical pneumocytes, kumburin interstitial da kumburin lymphocytic da aukuwar babban tantanin halitar multinucleated.
severe pneumonia: diffuse alveolar damage (DAD) with diffuse alveolar exudates.
matsanancin ciwon huhu: Rarrafa lalacewar alveolar (DAD) dakuma rarrafa alveolar exudate.
DAD is the cause of acute respiratory distress syndrome (ARDS) and severe hypoxemia.
DAD shine sanadiyyar alamun tsananin gajiyar hanyar numfashi wato respiratory distress syndrome (ARDS) tsanancin hypoxemia.
healing pneumonia: organisation of exudates in alveolar cavities and pulmonary interstitial fibrosis
warkas da namoniya: kungiyoyi na exudates a alveolar cavities da pulmonary interstitial fibrosis.
Blood: disseminated intravascular coagulation (DIC); leukoerythroblastic reaction
Jini: disseminated intravascular coagulation (DIC); amsawar leukoerythroblastic
Preventive measures to reduce the chances of infection include staying at home, avoiding crowded places, washing hands with soap and water often and for at least 20 seconds, practising good respiratory hygiene and avoiding touching the eyes, nose or mouth with unwashed hands.
Matakan rigakafin don rage yiwuwar kamuwa da cuta sun hada da kasancewa a gida, guje wa wuraren cunkoson jama'a, wanke hannu da sabulu da ruwa sau da yawa a kalla sekan 20, kulla da tsabtacen numfashi da kuma guje wa taɓa idanu, hanci ko baki tare da hannayen marasa wankewa.
The CDC recommends covering the mouth and nose with a tissue when coughing or sneezing and recommends using the inside of the elbow if no tissue is available.
CDC ta ba da shawarar rufe bakin da hanci da tolet papper yayin tari ko atishawa takuma badar da shawarar yin amfani da gwiwar hannu idan ba a sami tolet papper ba.
Proper hand hygiene after any cough or sneeze is encouraged.
Tsabtacewar hannu bayan kowane tari ko atishawa ana ƙarfafa shi.
The CDC has recommended the use of cloth face coverings in public settings, in part to limit transmission by asymptomatic individuals.Social distancing strategies aim to reduce contact of infected persons with large groups by closing schools and workplaces, restricting travel and cancelling large public gatherings.
CDC ta ba da shawarar yin amfani da mayafin rufe fuska a cikin wurin zaman jama'a, a wani ɓangare don iyakance watsa cutar daga mai alamun cutar. Tsarin nesantawa daga jama’a nufin sa domin rage huldawa da wanda ya kamu da cutar da babban tarin mutane ta hanyar rufe makarantu da wuraren aiki da ƙuntatawa tafiye-tafiye da soke babban taron jama'a.
Distancing guidelines also include that people stay at least 6 feet (1.8 m) apart.
Ka’idojin nisanta sun shafi mutane su ba da ratan akalla kafa 6 (1.8 m) a gefe.
There is no medication known to be effective at preventing COVID-19.As a vaccine is not expected until 2021 at the earliest, a key part of managing COVID-19 is trying to decrease the epidemic peak, known as "flattening the curve".
Babu wani magani da aka sani da zai yi tasiri don hana COVID-19. Kamar maganin rigakafi, ba zaton sa yanzu sai farin shekara 2021, wani mahimmin sashi na gudanar da COVID-19 shi ne ƙoƙarin rage ganiyar annoban, da aka sani da "karkatar da doron layin" wato flattening the curve.
The CDC also recommends that individuals wash hands often with soap and water for at least 20 seconds, especially after going to the toilet or when hands are visibly dirty, before eating and after blowing one's nose, coughing or sneezing.
CDC sun bayar da shawarar cewa mutane su rika wanke hannaye sau da yawa da sabulu da ruwa na tsawon kimanin sakan 20, musamman bayan an je ba haya ko hannaye sun yi datti a bayyane, kafin cin abinci ko bayan an hura hanci, tari ko atishawa.
It further recommends using an alcohol-based hand sanitiser with at least 60% alcohol, but only when soap and water are not readily available.For areas where commercial hand sanitisers are not readily available, the WHO provides two formulations for local production.
Ya kuma ƙara bada shawarar yin amfani da ruwan wanke hannu mai sinadarin kashe kwayoyin cuta mai aqalla sinadarai kashi 60%, Amma sai lokacin da babu sabulu da ruwa akusa, dakuma yankunan da basu wadata da amfani da sanidarin wanke hannu ba. WHO ta samar da tsari guda biyu don samar da abubuwan cikin gida.
In these formulations, the antimicrobial activity arises from ethanol or isopropanol.
A cikin wadannan tsari, aikin kashe karfin kananan halittu da ido ba ya iya gani ya taso ne daga sinadaran giya, wato ethanol ko isopropanol.
Hydrogen peroxide is used to help eliminate bacterial spores in the alcohol; it is "not an active substance for hand antisepsis".
Ana amfani da Hydrogen peroxide domin cire ramukan kwayoyin cuta a cikin giya; ba shi da inganci domin tsaftace hannu.
Glycerol is added as a humectant.
An qara glycerol a matsayin humectant.
People are managed with supportive care, which may include fluid therapy, oxygen support, and supporting other affected vital organs.
Ana sarrafa mutane da kulawa mai tallafi, wanda zai iya hadawa da ruwan magani, na'urar bada numfashi da tallafa wa wasu gabobin da abin ya shafa.
The CDC recommends that those who suspect they carry the virus wear a simple face mask.
CDC ta bayar da shawara cewa wadanda ake zargi da cewa suna dauke da kwayar cutan su sanya abin rufe fuska.
Extracorporeal membrane oxygenation (ECMO) has been used to address the issue of respiratory failure, but its benefits are still under consideration.
An yi amfani da Extracorporeal membrane oxygenation (ECMO) domin taimaka wa masu matsalan zuciya bisa dalilin rashin samun numfashi, amma ba a tabbatar da amfaninsa ba.
Personal hygiene and a healthy lifestyle and diet have been recommended to improve immunity.
An bada shawarar tsabtacewar mutum da ingantaccen tsarin lafiyan rayuwa da abinci don inganta garkuwar jiki.
Supportive treatments may be useful in those with mild symptoms at the early stage of infection.The WHO and Chinese National Health Commission have published recommendations for taking care of people who are hospitalised with COVID-19.
Taimako mai taimako yana da amfani a cikin waɗanda ke da jiyya mai sauƙi a farkon kamuwa da cuta WHO da hukumar kula da lafiya ta kasar china sun wallafa shawarwari game da kula da asibiti da marassa lafiya dake dauke da kwayar cutar COVID-19.
Intensivists and pulmonologists in the U.S. have compiled treatment recommendations from various agencies into a free resource, the IBCC.
Intensivists da pulmonologists a U.S sun samar da hanyoyin jiyya daga hukumomi dabam-dabam, wato IBCC.
As of April 2020, there is no specific treatment for COVID-19.
Tun daga Afrilu 2020 babu takamaiman maganin ƙwayar cutar ta COVID-19.
For symptoms, some medical professionals recommend paracetamol (acetaminophen) over ibuprofen for first-line use.
Don alama, wasu ƙwararru likitoci sun ba da shawarar fara anfani da paracetamol akan ibuprofin.
Precautions must be taken to minimise the risk of virus transmission, especially in healthcare settings when performing procedures that can generate aerosols, such as intubation or hand ventilation.
Dole a dauki matakan kariya domin rage yaduwan kwayan cutan, musamman a ma’aikatun lafiya yayinda ake zatas da ayukan da ke iya kirkiro aerosols kamar su hand ventilators, wato injin shakar iska.
For healthcare professionals caring for people with COVID-19, the CDC recommends placing the person in an Airborne Infection Isolation Room (AIIR) in addition to using standard precautions, contact precautions and airborne precautions.The CDC outlines the guidelines for the use of personal protective equipment (PPE) during the pandemic.
Masu kiwon lafiya da ke kula da mutane masu COVID-19, CDC ta bayar da shawaran sanya mutumin cikin AIIR, wato dakin da aka kebe tare da kiyayewa, kiyaye haduwa da kiyayewan iska. CDC sun bayyana ka’idoji na amfani da kayan kare kai (PPE) a lokacin anoban.
The recommended gear is: PPE gown, respirator or facemask, eye protection, and medical gloves.When available, respirators (instead of facemasks) are preferred.
Kayan sa jiki wanda aka bada shawarar shine: PPE, na’urar numfashi ko kariyar rufe fuska, kariyar ido, da safofin hannu. Lokacin da akwai, na’urar numfashi (maimakon kariyar fuska) an fi son su.
N95 respirators are approved for industrial settings but the FDA has authorised the masks for use under an Emergency Use Authorisation (EUA).
Ana ba da izinin na’urar numfashi N95 ga wuraren masana'antu amma FDA ta ba da izinin kariyar rufe fuska a ƙarƙashin Izinin Amfani mai Gaggawa (EUA).
They are designed to protect from airborne particles like dust but effectiveness against a specific biological agent is not guaranteed for off-label uses.
An tsara su don kare abubuwa daga barbashin iska kamar ƙura amma na da inganci akan takamaiman wakilin Halittu wanda bashi da lamunin ga shan magani ba tare da izinin likita ba.
When masks are not available, the CDC recommends using face shields or, as a last resort, homemade masks.
Lokacin da babu takunkumi, CDC ta ba da shawarar amfani da garkuwar fuska or irin takunkumin da ake hadawa a gida.
Most cases of COVID-19 are not severe enough to require mechanical ventilation or alternatives, but a percentage of cases are.
Nau'in ƙwayar cutar ta COVID-19 batayi tsananin daya isa ta buƙaci samun iska ko kuma madadin haka, amman wasu lokata akan samu.
The type of respiratory support for individuals with COVID-19 related respiratory failure is being actively studied for people in hospital, with some evidence that intubation can be avoided with a high flow nasal cannula or bi-level positive airway pressure.
Ana yin nazarin nau'in tallafin na numfashi ga mutane da ke da cutar ta hanyar COVID-19 da ke fama da matsalar numfashi ga mutanen da ke asibiti, tare da wasu shaidun da ke nuna cewa za a iya hana intabalation tare da hauhawar hanci da jijiyoyi ko matattarar karfin iska.
Whether either of these two leads to the same benefit for people who are critically ill is not known.
Ba a sani ba ko daya daga cikin wadannan biyu zai iya samar da wani amfani iri daya ga mutanen da suke fama da matsananciyar rashin lafiya.
Some doctors prefer staying with invasive mechanical ventilation when available because this technique limits the spread of aerosol particles compared to a high flow nasal cannula.Severe cases are most common in older adults (those older than 60 years, and especially those older than 80 years).
Wasu likitocin sunfi son tsarin iska na invasive idan yasamu saboda wamnan tsarin yana tsaƙaita yaduwa abubuwan aerosol, idan aka kwatanta da wucewar nasal cannula. Matsananci cutar sunfi kamuwa da tsofaffi(wayanda suka zarce shekaru 60, mussan masu shekaru 80).
Many developed countries do not have enough hospital beds per capita, which limits a health system's capacity to handle a sudden spike in the number of COVID-19 cases severe enough to require hospitalisation.
Kasashe masun tasowa dayawa ba su da isashen gadajen asibiti ko wace mallaka, wanda ya rage karfin tsarin lafiya ga iya rikewar tashin yawan masu kamuwa da COVID-19 mai tsananin sosai wanda ke bukatar gama gado a asibiti.
One study in China found 5% were admitted to intensive care units, 2.3% needed mechanical support of ventilation, and 1.4% died.
Wata bincike a China ta gano cewa an shigar da kashi biyar (5%) cikin dakin jiyya na masu mawuyacin hali, kashi 2.3% na bukatan taimakawa da injin shakar iska, sannan 1.4% sun mutu.
In China, approximately 30% of people in hospital with COVID-19 are eventually admitted to ICU.
A China, kusan kashi talatin (30%) na mutanen da ke asibiti da COVID-19 kan samu shiga sashen gaggawa wato ICU.
Mechanical ventilation becomes more complex as acute respiratory distress syndrome (ARDS) develops in COVID-19 and oxygenation becomes increasingly difficult.
Gudun iska yana zama mafi rikitarwa yayin da ciwo mai raunin numfashi (ARDS) ke tasowa a cikin COVID-19 kuma oxygenation ya zama da wahala.
Ventilators capable of pressure control modes and high PEEP are needed to maximise oxygen delivery while minimising the risk of ventilator-associated lung injury and pneumothorax.
Na’urar bada iska wato Ventilators mai tsarafawa ta hanyar matsin iska da PEEP, ana buƙatar su domin ƙara girmar ba da iska, yayin da an rage hadarin samun ciwon da ke da alaka da na’urar iska da pneumothorax.
High PEEP may not be available on older ventilators.
Dogon PEEP ba zai iya samunwa ba a tsohon na’urar bada iska.
Research into potential treatments started in January 2020, and several antiviral drugs are in clinical trials.
Bincike a kan hanyoyin jiyya ta fara a Janairu 2020, kuma ana kan gwajin magunguna na yaki da cututtuka da dama.
Remdesivir appears to be the most promising.
Remdesivir ya bayyana a matsayin mafi cikawa.
Although new medications may take until 2021 to develop, several of the medications being tested are already approved for other uses or are already in advanced testing.
Ko da yake Sabbin magunguna za su iya ɗaukar lokaci har zuwa 2021 kafin a haɓaka su. An riga an amince da yawancin magungunan da ake gwaji domin wadansu amfani ko suna gwajin da ya yi gaba.
Antiviral medication may be tried in people with severe disease.
Za a iya gwada maganin jiyyan kwayan cutar mutane masu tsananin ciwo.
The WHO recommended volunteers take part in trials of the effectiveness and safety of potential treatments.The FDA has granted temporary authorisation to convalescent plasma as an experimental treatment in cases where the person's life is seriously or immediately threatened.
WHO ta shawarci masu sa kai su shiga cikin hanyoyin inganci, tasiri da amincin yiwuwar magani. FDA ta ba da izini na wucin gadi don convalescent plasma a matsayin gwajin daya shafi rayuwar mutum cikin hatsari.
It has not undergone the clinical studies needed to show it is safe and effective for the disease.
Ba a riga an yi binciken asibiti wanda ake bukata ba don nuna cewa za a iya amfani da shi kuma tana da muhimanci ga cutar.
In February 2020, China launched a mobile app to deal with the disease outbreak.
A watan Fabrairu na 2020 china ta ƙaddamar da manhajar waya don magance barkewar cutar.
Users are asked to enter their name and ID number.
Akan bukaci masun amfani su shigar da suna da lambar ID.
The app is able to detect 'close contact' using surveillance data and therefore a potential risk of infection.
Manhajar nada daman gano mutane na kusa kuma nayin amfani da bayanan sa ido, don haka haɗari da iyuwar kamuwa da cuta.
Every user can also check the status of three other users.
Kowanne mai amfani zai iya duba matsayin masu amfani guda uku.
If a potential risk is detected, the app not only recommends self-quarantine, it also alerts local health officials.Big data analytics on cellphone data, facial recognition technology, mobile phone tracking and artificial intelligence are used to track infected people and people whom they contacted in South Korea, Taiwan and Singapore.
Idan an gano yiwuwar haɗarin, ba kebewar kai kadai manhajar ya shawarta ba, yana iya fadakar da jami’an kiwon lafiya na cikin gida. Nazarcewar babban bayanan kan bayanan waya, fasahar gane fuska, bin sawu da waya da fasaha na wucin gadi ana amfani da don gano mutanen da ke kamuwa da cuta, Kuma mutanen da suka yi tuntuba cikin Koriya ta Kudu, Taiwan da Singapore.
In March 2020, the Israeli government enabled security agencies to track mobile phone data of people supposed to have coronavirus.
A cikin Maris 2020 gwamnatin Isra'ila ta ba hukumomin tsaro damar bin diddigin bayanan wayar hannu na mutanen da ke dauke da kwayar cutar Corona.
The measure was taken to enforce quarantine and protect those who may come into contact with infected citizens.
An dauki matakan domin tabbatar da killacewa domin tsare wadanda suke hulda da wanda suna da cutan.
Also in March 2020, Deutsche Telekom shared aggregated phone location data with the German federal government agency, Robert Koch Institute, in order to research and prevent the spread of the virus.
Kuma a watan Maris 2020, Deutsche Telekom ta raba wurare na waya da data da hukuman gwamnatin tarayya na Gemany, Robert Koch Institute, domin bincika hanyoyi na yaki da yaduwan cutan.
Russia deployed facial recognition technology to detect quarantine breakers.
Rasha ta tura fasahar amincewa da fasahar gano fuska don gano masu ketare dokan kebewa.
Italian regional health commissioner Giulio Gallera said he has been informed by mobile phone operators that "40% of people are continuing to move around anyway".
kwamishinar lafiya na Italy, Giulio Gallera, ya ce masu sarafa wayar hannu sun sanar masa da cewa kashi arba’in (40%) na mutane suna ci gaba yawonsu.
German government conducted a 48 hours weekend hackathon with more than 42.000 participants.
Gwamnatin Jamus ta gudanar da wani shiri na hutun karshen mako 48 tare da mahalarta taron sama da 42,000.
Also the president of Estonia, Kersti Kaljulaid, made a global call for creative solutions against the spread of coronavirus.
Hakanan shugaban Estonia, Kersti Kaljulaid ya yi kiran ga duniya don samun mafita, akan yaduwar cutar ta Corona.
Individuals may experience distress from quarantine, travel restrictions, side effects of treatment or fear of the infection itself.
Mutane na iya samun matsala a ta dalilin killacewa, dokoki a kan tafiye-tafiye, illan jiyya ko kuma tsoron kamuwa da cutan kanta.
BBC quoted Rory O'Connor in saying, "Increased social isolation, loneliness, health anxiety, stress and an economic downturn are a perfect storm to harm people's mental health and wellbeing."
BBC ta nakalto Rory O'Connor yana cewa, "Karuwar warewar jama'a, kadaici, damuwar rashin lafiya, gajiya da kuma durkushewar tattalin arziki sune cikakkiyar guguwa da zata cutar da lafiyar kwakwalwa mutane da kuma lafiyar jama'a."
The disease may take a mild course with few or no symptoms, resembling other common upper respiratory diseases such as the common cold.
Wannan cuta na iya shiga ta hanya mai sauki tare da kaɗan ko babu alamun, masu kama da cutar lumphashi, irinsu mura na yauda kullum.
Mild cases typically recover within two weeks, while those with severe or critical diseases may take three to six weeks to recover.
Masu nuna dan rashin lafiyar kan warke cikin sati biyu, sannan masu sananin cutar na iya daukan sati uku zuwa shida kafin warkewa.
Pregnant women may be at higher risk for severe infection with COVID-19 based on data from other similar viruses, like SARS and MERS, but data for COVID-19 is lacking.In some people, COVID-19 may affect the lungs causing pneumonia.
Matan da ke da juna biyu na iya kasancewa cikin haɗari mafi girma ga kamuwa da cuta da COVID-19 dangane da bayanai daga wasu ƙwayoyin cuta masu kama da wannan, kamar SARS da MERS, amma bayanai don COVID-19 ba su da yawa. A cikin wasu mutane, COVID-19 na iya shafar huhun da ke haifar da cutar huhu.
In those most severely affected, COVID-19 may rapidly progress to acute respiratory distress syndrome (ARDS) causing respiratory failure, septic shock or multi-organ failure.
A cikin wadanda cutar ta fi shafa, COVID-19 na iya ci gaba da hanzari zuwa cuta hanyoyin numfashi mai tsananin gajiyar alamar cutan (ARDS) (ARDS) wanda ke haifar da gazawar hanyoyin numfashi, girgiza septic ka gazawar gabobin jiki da yawa.
Complications associated with COVID-19 include sepsis, abnormal clotting and damage to the heart, kidneys and liver.
Wahalan da ke da alaka dai COVID-19 sun haɗa da sepsis, daskarewar jini wanda ba a ka’ida ba ne da lalacewar zuciya, koda da hanta.
Clotting abnormalities, specifically an increase in prothrombin time, have been described in 6% of those admitted to hospital with COVID-19, while abnormal kidney function is seen in 4% of this group.
Matsalan daskarewan jini, musamman karuwa na lokacin daskarewa. An bayyana cewa a kashi shida (6%) na wadanda aka shigar da su asibita da COVID-19, masu matsalan koda kuma suna kashi hudu (4%) na wannan rukuni.
Approximately 20-30% of people who present with COVID-19 demonstrate elevated liver enzymes (transaminases).
Kimanin kashi 20-30% na mutanen da su ke da kwayar cutar COVID-19 suna nuna girman enzymes na hanta (Transaminases).
According to the same report, the median time between onset of symptoms and death was ten days, with five being spent hospitalised.
A cewar rahoton daya, lokacin tsakanin farkon bayyanar cutar da mutuwa ya kasance kwana goma ne, da shafewar kwana biyar a asibiti.
However, patients transferred to an ICU had a median time of seven days between hospitalisation and death.
Duk da haka, marasa lafiya wanda aka juya zuwa ICU suna da tsawon kwanaki bakwai tsakanin bada gado a asibiti da mutuwa.
In a study of early cases, the median time from exhibiting initial symptoms to death was 14 days, with a full range of six to 41 days.
A cikin nazarin lokuta na farko, tsaka-tsakan lokaci daga nuna alamun farko zuwa mutuwa ya kasance kwanaki 14, tare da cikakken kewayon kwanaki shida zuwa 41.
In a study by the National Health Commission (NHC) of China, men had a death rate of 2.8% while women had a death rate of 1.7%.
A cikin binciken da Hukumar Kula da Lafiya ta Kasar China (NHC), mazaje suna da yawan mutuwa kashi 2.8% yayin da mata sukan mutu da kashi 1.7%.
Histopathological examinations of post-mortem lung samples show diffuse alveolar damage with cellular fibromyxoid exudates in both lungs.
Binciken Histopathological na samfurorin huhun gawaki ta nuna lalacewa alveola da tantanin halitar fibromyxoid wanda sun fito daga huhun biyu.
Viral cytopathic changes were observed in the pneumocytes.
Kwayar cutar kuma an lura da canje-canje a cikin pneumocyte.
The lung picture resembled acute respiratory distress syndrome (ARDS).
Hoton huhu ya yi kama da cuta hanyoyin numfashi mai tsananin gajiyar alamar cutan (ARDS).
In 11.8% of the deaths reported by the National Health Commission of China, heart damage was noted by elevated levels of troponin or cardiac arrest.
A cikin kashi 11.8% na mutuwar da hukumar lafiya ta kasar ta ruwaito, an lura da lalacewar zuciya ta hanyar haɓaka matakan troponin ko bugun zuciya.
According to March data from the United States, 89% of those hospitalised had preexisting conditions.Availability of medical resources and the socioeconomics of a region may also affect mortality.
A cewar bayanan Maris daga kasar amerika kashi 89% na waɗanda ke asibiti sunada wannan yanayin. Kasancewar albarkatun likita da tattalin arziƙin yanki ma na iya shafar mace-mace.
Estimates of the mortality from the condition vary because of those regional differences, but also because of methodological difficulties.
Kimantawa na mace-mace daga wannan yanayi ya bambanta saboda bambanci tsakanin yanki da kuma wahalan gudanarwa.
The under-counting of mild cases can cause the mortality rate to be overestimated.
Rashin kirga sabbin masu kamuwa da kananan cuta na iya jawo kirga mutuwar da yawa kuma zai wuce gona da iri.
However, the fact that deaths are the result of cases contracted in the past can mean the current mortality rate is underestimated.
Duk da haka, gaskiyar magana game da mutuwar shine sakamakon cuta da aka samu a baya na iya nuni an rena takamamman yawar mutuwa na yanzu.
Smokers were 1.4 times more likely to have severe symptoms of COVID-19 and approximately 2.4 times more likely to require intensive care or die compared to non-smokers.Concerns have been raised about long-term sequelae of the disease.
Masu shan sigari sun kasance lokaci sau 1.4 mafi yiwuwar samun mummunar cutar COVID-19 kuma kusan sau 2.4 na iya buƙatar kulawa mai zurfi ko mutuwa idan aka kwatanta da wayanda basa shan sigari, an nuna damuwa game da dogon lokaci sequelae na cutan.
The Hong Kong Hospital Authority found a drop of 20% to 30% in lung capacity in some people who recovered from the disease, and lung scans suggested organ damage.
Hukuma Asibitin Hong Kong ta sami raguwar 20% zuwa 30% a cikin karfin huhun da wasu suka warke daga cutar, kuma binciken huhun yana nuna lalacewar jikin mutum mutane.
This may also lead to post-intensive care syndrome following recovery.
Wannan na iya jawo wata matsala bayan an warke.
As of March 2020, it was unknown if past infection provides effective and long-term immunity in people who recover from the disease.
A Maris 2020 dai, ba a riga an sani ko wadanda suka yi fama da cutan sun warke, ko suna da dogon kariya daga cutan ba.
Immunity is seen as likely, based on the behaviour of other coronaviruses, but cases in which recovery from COVID-19 have been followed by positive tests for coronavirus at a later date have been reported.
An ga garkuwa, bisa ga halayan wasu coronavirus, amma akwai lamarin masu kamuwa da cutan wadanda suka warke daga COVID-19 an sake masu gwajin gaskiya don coronavirus a lokacin gaba aka bada rahoton.
These cases are believed to be worsening of a lingering infection rather than re-infection.
Ana ganin wadannan damu’oin sun kara fadada kamuwa da cuta ne maimakon sake kamuwa da cuta.
The virus is thought to be natural and have an animal origin, through spillover infection.
Kwayar cutar ana tunanin halitta ce kuma tana da asalin dabba, ta hanyar kamuwa da cuta.
The actual origin is unknown, but by December 2019 the spread of infection was almost entirely driven by human-to-human transmission.
Ba a san ainihin asalin ba, amma har zuwa Disamba 2019 yaduwar kamuwa da cutar ya kusan karɓar watsa ta mutum-da-mutum.
A study of the first 41 cases of confirmed COVID-19, published in January 2020 in The Lancet, revealed the earliest date of onset of symptoms as 1 December 2019.
Bincikan masun kamuwa da cutar COVID-19 su guda 41,wanda aka walafa a Janairu 2020 a Lancet, ya nuna cewa ranar farko na alamun cutan rana 1 ga watan Disamba 2019 ne.
Official publications from the WHO reported the earliest onset of symptoms as 8 December 2019.
Hukumar Lafiya ta Duniya sun sanar cewa farkon alamun cutan ya fito ne a ranar 8 Disamba, 2019.
Several measures are commonly used to quantify mortality.
Ana amfani da yawancin matakan domin sauƙaƙe mace-mace
These numbers vary by region and over time and are influenced by the volume of testing, healthcare system quality, treatment options, time since initial outbreak and population characteristics such as age, sex and overall health.
Waɗannan lambobin sun bambanta daga yanki da kuma suna rinjaya da girman gwaji a kan lokaci, Ingancin tsarin kiwon lafiya, zaɓuɓɓukan jiyya, lokaci tun lokacin barkewa da yanayin yawan jama'a irin su shekaru, mace ko na miji da dukan lafiya.
In late 2019, WHO assigned the emergency ICD-10 disease codes U07.1 for deaths from lab-confirmed SARS-CoV-2 infection and U07.2 for deaths from clinically or epidemiologically diagnosed COVID-19 without lab-confirmed SARS-CoV-2 infection.The death-to-case ratio reflects the number of deaths divided by the number of diagnosed cases within a given time interval.
A karshen shekara ta 2019, WHO ta sanya dokar ta baci ICD-10 lamba U07.1 don mutuwa daga tabacin dakin gwajin kamuwa da cutan SARS-CoV-2 da U07.2 Don mutuwar asibiti ko binciken epidemiologically COVID-19 ba tere da amincewar kamuwa da SARS-CoV-2 a dakin gwaji ba. Yawan mutuwa don kamuwa da cutar ya nuna lambar mutuwa wanda za a raba da lambar wadanda aka sami cutar a wata tsawon lokaci.
Based on Johns Hopkins University statistics, the global death-to-case ratio is 6.9% (153,822/2,240,191) as of 17 April 2020.
Dangane da ƙididdigar jami'ar John's Hopkins adadin mutuwar duniya shine kashi 6.9% (153, 822/2, 240,191)a 17 ga watan Afrilu 2020.
The number varies by region.Other measures include the case fatality rate (CFR), which reflects the percent of diagnosed individuals who die from a disease, and the infection fatality rate (IFR), which reflects the percent of infected individuals (diagnosed and undiagnosed) who die from a disease.
Lambobin sun bambanta daga yanki, Sauran matakan sun hada da yanayin yawan haihuwa (CFR) Wanda ya nuna adadin mutane,(wayanda aka binciki lafiyarsu dakuma wayanda ba'a binciki lafiyarsuba) wayanda suka mutu daga cutar.
These statistics are not time bound and follow a specific population from infection through case resolution.
Wadanan ƙididdigar ba su daɗewa ba kuma sun bi takamaiman yawan jama'a daga kamuwa da cuta ta hanyar warkarwar cutan.
While not all infected people develop antibodies, the presence of antibodies may provide information about how many people have been infected.
Ko da yake ba duka mutane ke da garkuwar jiki da ke yakin cututtuka ba, kasancewan sinadaran na iya samar da bayani a kan yadda mutane masu yawa suka kamu da cutan.
In the epicentre of the outbreak in Italy, Castiglione d'Adda, a small village of 4600, 80 (1.7%) are already dead.
A cikin barkewar annobar a Italiya, Castiglione d'Adda, ƙaramin ƙauyen 4600, 80 (1.7%) sun riga sun mutu.
In Gangelt, the disease was spread by Carnival festivals, and spread to younger people, causing a relatively lower mortality, and not all COVID-19 deaths may have been formally classified as such.
A Genglet, cutar ta yaduwa neh a lokacin bikin Carnival, Kuma yaduwa ga matasa sanadin mace-mace mafi sauki kuma ba duk muttuwa don cutar COVID-19 bace aka tsara ta irin wanna.
Furthermore, the German health system has not been overwhelmed.
Bayan haka kuma ba a shawo kan tsarin lafiyar Jamusawa ba.
In the Netherlands, about 3% may have antibodies, as assessed from blood donors.
A kasar Netherlands, kimanin kashi uku (3%) na da sinadaran yakan cututtuka, wato yadda aka tantance daga masu bayar da jini.
69 (0.004% of the population) have been confirmed to have died from COVID-19.
mutane 69 (kashi 0.004% na yawan jama’a) An tabbatar da cewa sun mutu daga kwayar cutar COVID-19.
The impact of the pandemic and its mortality rate are different for men and women.
Tasirin annoban da yawan mace-mace tana da bambanci tsakanin maza da mata.
Mortality is higher in men in studies conducted in China and Italy.
A wata bincike da aka yi a China da Italy, ya nuna cewa mutuwa ya fi yawa a cikin maza
The highest risk for men is in their 50s, with the gap between men and women closing only at 90.
Mafi hadarin kamuwa a maza sune wadanda shekaru su ya kai 50 zuwa sama, da bambanci tsakanin maza da mata kusa da 90 kawai.
In China, the death rate was 2.8 percent for men and 1.7 percent for women.
A cikin China adadin maza ya mutu kashi 2.8 ne ga maza kuma kashi 1.7 na mata ne.
The exact reasons for this sex-difference is not known, but genetic and behavioural factors could be a reason.
ba a san dalilin da ya sa akwai bambanci tsakanin maza da mata ba amma kwayoyi da abubuwa da suka shafi halaya na iya zama dalili.
Sex-based immunological differences, lesser prevalence of smoking in women and men developing co-morbid conditions such as hypertension at a younger age than women could have contributed to the higher mortality in men.
Bambancin karewan jiki tsakanin maza da mata, rashin yawan shan hayaki kamar sigari a mata sannan maza na kamuwa da hawan jini da wuri a bisan mata ya kara yawan mutuwa a maza.
In Europe, 57% of the infected individuals were men and 72% of those died with COVID-19 were men.
A kasashen Turai, kashi 57% na masu dauke da cutan maza ne, sannan kashi 72% da suka mutu daga cutan COVID-19 maza ne.
As of April 2020, the US government is not tracking sex-related data of COVID-19 infections.
Tun daga watan Afrilun 2020 gwamnatin Amurka ba ta banbance mace ko namiji da ke tattare da cutar COVID-19.
Research has shown that viral illnesses like Ebola, HIV, influenza and SARS affect men and women differently.
Bincike ta nuna cewa ciwo daga kwayoyin cututtuka kamar Ebola, HIV, mura da SARS na shafe maza da mata a lokaci dabam.
A higher percentage of health workers, particularly nurses, are women, and they have a higher chance of being exposed to the virus.
Kashi mafi yawa na ma’aikatan lafiya, wato masu aikin jiyya, mata ne, kuma suna da babban dama na kamuwa da kwayar cutan.
The World Health Organization announced on 11 February 2020 that the official name of the disease would be "COVID-19".
Hukumar Lafiya Ta Duniya ta yi sanarwa ranar 11 ga watan Fabrairu 2020 cewa sunan cutar za ta kasance "COVID-19" bisa hukuma.
WHO chief Tedros Adhanom Ghebreyesus explained that CO stands for corona, VI for virus, D for disease, and 19 for when the outbreak was first identified: 31 December 2019.
Shugaban WHO Tedros Adhanom Ghebreyesus yayi bayanin cewa CO tsaye ga corona, VI ga ƙwayar cuta, D don cuta, da 19 don lokacin da aka fara gano cutar: 31 Disamba 2019.
The name had been chosen to avoid references to a specific geographical location (e.g. China), animal species or group of people, in line with international recommendations for naming aimed at preventing stigmatisation.The virus that causes COVID-19 is named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
An zabo sunan ne domin a gujewa tunanin mika yasa a wuri guda (a misali, China), jinsunan dabbobi ko mutane, daidai da yadda tsarin ambatan sunaye da ke neman kawas da wariya. An sa wa kwayar cutan da ta jawo COVID-19 sunan severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
The WHO additionally uses "the COVID-19 virus" and "the virus responsible for COVID-19" in public communications.
Hukumar Lafiya ta Duniya na amfani da “kwayar cuta COVID-19” da kuma “kwayan cuta wanda ke jawo COVID-19” a sadarwan jama’a.
Both the disease and virus are commonly referred to as "coronavirus".
Dukkanin cutar da kwayar cutar ana kiranta azaman ƙwayar “cuta corona”
During the initial outbreak in Wuhan, China, the virus and disease were commonly referred to as "coronavirus" and "Wuhan coronavirus".
A lokacin ɓarkewan farko a Wuhan China, kwayar cutar da cutar ana yawancin kiranta da cutar “coronavirus” da “coronavirus ta Wuhan”.
In January 2020, WHO recommended 2019-nCov and 2019-nCoV acute respiratory disease as interim names for the virus and disease in accordance with 2015 guidance against using locations in disease and virus names.
A Janairu 2020, Hukumar Lafiya na Duniya ta ba da shawaran 2019-nCoV da 2019-nCoV, ciwon numfashi mai sanani a matsayin sunayen wucin-gadi na kwayar cutan da cutan bisa ga ka’idojin 2015 kan amfani da wurare a jinsin cuta da kwayar cututtuka.
The official names COVID-19 and SARS-CoV-2 were issued on 11 February 2020.
An ba da sunan COVID-19 da SARS-CoV-2 ranar 11 Febrairu 2020.
Due to capacity limitations in the standard supply chains, some digital manufacturers are printing healthcare material such as nasal swabs and ventilator parts.
Saboda ƙarancin iya aiki a cikin wadataccen tsari, wasu masana'antun dijital suna buga kayan Kiwan lafiya kamar safurin hanci da sasshen bada iska.
In one example, when an Italian hospital urgently required a ventilator valve, and the supplier was unable to deliver in the timescale required, a local startup reverse-engineered and printed the required 100 valves overnight.
Awani misali, lokacinda wata asibit a qasar italiya ta buqaci na'urar iska da gaggawa, kuma wanda zaikawo ba zamu zuwa ba a lokacin da ake buqata, Injin juyawa na gida aka fitar da fitar da valve 100 da ake bukata a daren.
After the initial outbreak of COVID-19, conspiracy theories, misinformation and disinformation emerged regarding the origin, scale, prevention, treatment and other aspects of the disease and rapidly spread online.
Bayan fitowan cutar COVID-19, ka’idar shirki, labarun karya sun fito a kan asali, sikeli, kariya da wasu bangarorin cutar da suka yadu da wuri a yanar gizo.
Humans appear to be capable of spreading the virus to some other animals.
'Yan Adam suna iya yada cutar zuwaga wasu dabbobi.
The study failed to find evidence of viral replication in pigs, ducks, and chickens.
Binciken ya gaza samun tabbacin kwayar cutar a aladu, agwagi da kaji.
No medications or vaccine is approved to treat the disease.
Babu wani magani ko allurar da aka yarda da shi don magance wannan cutar.
International research on vaccines and medicines in COVID-19 are underway by government organisations, academic groups and industry researchers.
Binciken kasa da kasa kan COVID-19 kungiyoyin gwamnati suna kan bincike, da kungiyar iliimi da binciken masana’antu.
In March, the World Health Organization initiated the "SOLIDARITY Trial" to assess treatment effects of four existing antiviral compounds with the most promise of efficacy.
A watan Maris, Hukumar Lafiya ta Duniya ta fara gwaji, wato “SOLIDARITY Trial” domin samun jiyya na maganin rigakafi guda hudu wadda ake sa zato za su yi inganci.
There is no available vaccine, but various agencies are actively developing vaccine candidates.
Babu rigakafi, amma hukumomi dabam-dabam suna kokarin samo rigakafin.
Previous work on SARS-CoV is being utilised because SARS-CoV and SARS-CoV-2 both use the ACE2 receptor to enter human cells.
Ana kan amfani da aiki na baya a kan SARS-CoV saboda SARS-CoV da SARS-CoV-2 duk na amfani da ACE2 domin shiga jikin mutum.
There are three vaccination strategies being investigated.
Akwai hanyoyi guda uku da ake bi don gano wuri.
First, researchers aim to build a whole virus vaccine.
Da farko, masu binciken suna da niyyar samo maganin rigakafin kwayar cuta.
The use of such a virus, be it inactive or dead, aims to elicit a prompt immune response of the human body to a new infection with COVID-19.
Amfani da irin wannan kwayar cuta ko mara illa ko matacce, na neman tabo karewa na gaggawa a jikin mutum da sabon kamuwa da COVID-19.
A second strategy, subunit vaccines, aims to create a vaccine that sensitises the immune system to certain subunits of the virus.
Hanya ta biyu, fannin rigakafi, ana neman samo rigakafin da zai taimaka wurin yakan wasu fannin cutar.
In the case of SARS-CoV-2, such research focuses on the S-spike protein that helps the virus intrude the ACE2 enzyme receptor.
Game da SARS-CoV-2, irin wannan binciken yana maida hankali ne akan sinadarin S-Spike wanda ke taimakawa kwayar cutar kutsawa cikin karuwar enzayam ACE2.
A third strategy is that of the nucleic acid vaccines (DNA or RNA vaccines, a novel technique for creating a vaccination).
Dabaru na uku shine na maganin rigakafi na nucleic acid (DNA ko rigakafin RNA, sabbin hanyoyin kirkiro maganin rigakafi).
Experimental vaccines from any of these strategies would have to be tested for safety and efficacy.On 16 March 2020, the first clinical trial of a vaccine started with four volunteers in Seattle.
Allurar rigakafi daga kowanne dole ne a gwada su don aminci da inganci 16 ga watan marus a shekarar 2020, Trawarin farko na kamfanin maganin alurar riga kafi tare da masu bada agaji huɗu a Seattle.
The vaccine contains a harmless genetic code copied from the virus that causes the disease.Antibody dependent enhancement has been suggested as a potential challenge for vaccine development for SARS-COV-2, but this is controversial.
Maganin alurar rigakafi na dauke da lambar kwayan halitta mara illa da aka kofe daga kwayar cutar da ke kawo ciwon. An ba da shawaran habaka sinadarai masu yakan cututtuka a matsayin hanyar samar da maganin rigakafin SARS-COV-2, amma akwai gardama.
There are more than 300 active clinical trials underway as of April 2020.
Akwai mutane fiye da 300 wanda ake son gwaji a asibitin daga watan Afrilu 2020.
Seven trials were evaluating already approved treatments for malaria, including four studies on hydroxychloroquine or chloroquine.
Hanyoyi gwaji bakwai an riga ana kimantawa aminciwar jinyar zazzabin, har da bincike hudu akan hydrochloricquine da chloroquine.
Repurposed antiviral drugs make up most of the Chinese research, with nine phase III trials on remdesivir across several countries due to report by the end of April.
Binciken Chinese ta kunshi magungunan rigakafin, an kuma samu matakai tara na gwaji kan remdesivir a kasashe da yawa saboda rohoto a karshen Afrilu.
A dynamic review of clinical development for COVID-19 vaccine and drug candidates was in place, as of April 2020.Several existing antiviral medications are being evaluated for treatment of COVID-19, including remdesivir, chloroquine and hydroxychloroquine, lopinavir/ritonavir and lopinavir/ritonavir combined with interferon beta.
Yin bita mai zurfi game da haɓaka asibiti don maganin rigakafin ƙwayar cutar COVID-19 da maganin gwaji suna nan. tun watan Afrilu 2020. Ana kimmantawa yawancin maganin kariya daga kwayan cutar don jinyar COVID-19, ya hada da remdesivir chloroquine da hydroxychloroquine, looinavir/ritonavir da lopinavir/ritomavir hadi da inyerferon beta.
There is tentative evidence for efficacy by remdesivir, as of March 2020.
Akwai alamun shaida na inganci ta wurin remdesivir, daga Maris 2020.
Clinical improvement was observed in patients treated with compassionate-use remdesivir.
An ga alaman sauki a marasa lafiya da aka yi jiyya da amfani da remdesivir.
Phase III clinical trials are being conducted in the US, China and Italy.Chloroquine, previously used to treat malaria, was studied in China in February 2020, with preliminary results.
Ana gudanar da gwaji na asibiti na Phrase III a Amurka, china da italiya. Chloroquine A da can ana amfani da shi don maganin zazzabin cizon sauro, An yi nazarin karatun a cikin China a shekarar 2020 tate da saka mako na farko.
However, there are calls for peer review of the research.
Duk da haka, akwai kira da ake yi domin tabbatar da wannan bincike.
Korean and Chinese Health Authorities recommend the use of chloroquine.
Hukumomin lafiya na Koriya da China sun ba da shawarar yin amfani da chloroquine.
However, the Wuhan Institute of Virology, while recommending a daily dose of one gram, notes that twice that dose is highly dangerous and could be lethal.
Koyaya, jami'ar Wuhan ta ilimin cututtuka, tabada shawarwarin maganin anfani nayau da kullun na gram daya, asani cewa anfani da guda biyu yana da matuqar hadari kuma yakan iya jawo rasarai.
On 28 March 2020, the FDA issued an emergency use authorisation for hydroxychloroquine and chloroquine at the discretion of physicians treating people with COVID-19.The Chinese 7th edition guidelines also include interferon, ribavirin or umifenovir for use against COVID-19.
A ranar 28 ga Maris 2020, FDA sun ba da rohoton gaggawa domin ba da dama domin amfani da hydroxychloroquine da chloroquine a jiyyan mutane da ke fama da COVID-19. Ka’idojin Chinese bugu na 7 ta hada interferon, ribavirin ko umifenovir domin amfani kan COVID-19.
Preliminary data indicate that high doses of ribavirin are necessary to inhibit SARS-CoV-2 in vitro.
Bincike na baya ta nuna cewa daukan babban kashi na ribavirin na da muhimmancin yakin SARS-CoV-2 a vitro.
Nitazoxanide has been recommended for further in vivo study after demonstrating low concentration inhibition of SARS-CoV-2.Studies have demonstrated that initial spike protein priming by transmembrane protease serine 2 (TMPRSS2) is essential for entry of SARS-CoV-2 via interaction with the ACE2 receptor.
An ba da shawaran amfani da Nitazoxanide domin karin bincike bayan nuna karancin yaki da SARS-CoV-2. Bincike ta nuna cewa farkon spike protein priming ta transmembrane protease serine 2 (TMPRSS2) na da muhimmanci domin shigan SARS-CoV-2 ta wurin alaka da mai karɓan ACE2.
The studies of chloroquine and hydroxychloroquine with or without azithromycin have major limitations that have prevented the medical community from embracing these therapies without further study.Oseltamivir does not inhibit SARS-CoV-2 in vitro and has no known role in COVID-19 treatment.
Binciken chloroquine da hydroxychloroquine tare da koba tare da azithromycin yanada babban iyakancewa wanda ya hana alumman likitanci shiga cikin karbar wadanan hanyoyin jinya ba tare da sake wata bincike ba. Oseltamivir baya hanuwa cikin kwalbar gwaji SARS-CoV-2 kuma ba shi da rawar da aka sani a cikin jinyar COVID-19.
Cytokine storm can be a complication in the later stages of severe COVID-19.
Guguwar Cytokine na iya zama matsala idan ciwon COVID-19 ta yi tsanani.
There is evidence that hydroxychloroquine may have anti-cytokine storm properties.Tocilizumab has been included in treatment guidelines by China's National Health Commission after a small study was completed.
Akwai alama cewa hydroxychloroquine na da sinadaran cytokine storm. China ta hada da tociizumab a ka’idojin jiyya bayan wata karamar bincike.
It is undergoing a phase 2 non randomised test at the national level in Italy after showing positive results in people with severe disease.
Yana cikin gwajin sashe na 2 gwaji wanda ba daga ko ina ba ne a kasar Italy bayan nuna sakamakon mutane masu tsananin ciwo.
Combined with a serum ferritin blood test to identify cytokine storms, it is meant to counter such developments, which are thought to be the cause of death in some affected people.
Hade da gwajin jini iri ta serum ferritin domin gano cytokine storms, aikinsa domin ya tsayar da wasu matsaloli wadda ake tsamanin ke jawo mutuwa a wasu mutane da ke dauke da cutan.
The interleukin-6 receptor antagonist was approved by the FDA based on retrospective case studies for treatment of steroid refractory cytokine release syndrome induced by a different cause, CAR T cell therapy, in 2017.
FDA ta yarda da kariyar interleukin-6 receptor antagonist dangane da nazarin yanayin da ake juyawa don magance cutarwar steroid refractory cytokine sakin alama wanda aka haifar da wani dalili daban, CAR T jinyar tantanin halitta, a cikin 2017.
To date, there is no randomised, controlled evidence that tocilizumab is an efficacious treatment for CRS.
Har wa yau babu bazuwar shaida da ta nuna tocilizumab na iya jiyyan CRS.
Transferring purified and concentrated antibodies produced by the immune systems of those who have recovered from COVID-19 to people who need them is being investigated as a non-vaccine method of passive immunisation.
Canja wurin tsarkakewa da tattarawar garkuwan jiki wanda aka samo ta wurin tsarin garkuwan jikin wadanda suka warke daga cutar COVID-19 zuwa mutane da ke bincika a matsayin hanyar mara bada maganin rigakafi.
This strategy was tried for SARS with inconclusive results.
Anyi kokarin wannan tsarin don SARS tare da rashin isashen sakamako.
Viral neutralisation is the anticipated mechanism of action by which passive antibody therapy can mediate defence against SARS-CoV-2.
Rage karfin kwayar cuta shi ne tsaring aiwatarwa wanda ke kara karfin garkuwar jiki don hada kariya daga SARS-CoV-2.
Other mechanisms however, such as antibody-dependent cellular cytotoxicity and/or phagocytosis, may be possible.
Ana iya samun wasu hanyoyi kuma kamar masu dogara ga sinadarai masu yakin cututtuka wato cellular cytotoxicity da phagocytosis.
Other forms of passive antibody therapy, for example, using manufactured monoclonal antibodies, are in development.
Wadansu siffofin kara karfin garkuwar jiki, misali, anfani da kerarran garkuwar jiki monoclonal wanda a ake habakawa.
Production of convalescent serum, which consists of the liquid portion of the blood from recovered patients and contains antibodies specific to this virus, could be increased for quicker deployment.
samarwa da convalescent serum, wanda ya kunshi fanni ruwa na jini wanda aka samo daga masu jiyya kuma na dauke da sinadarai masu yakin cuta daga wannan kwayan cutan, ana iya karawa domin amfani da wuri.
Coronavirus diseases, a group of closely related syndromes
Cutar coronavirus, rukuni ne na cututuka masu dangantakar alamu.